A tier · strong
Orforglipron is FDA-approved with a completed multi-trial phase 3 programme, but its weight-loss efficacy is roughly half that of tirzepatide and it has no cardiovascular outcomes data, so it ranks below the injectable leaders despite the genuine advance of oral, non-peptide delivery.
orforglipron
Orforglipron is a once-daily oral non-peptide GLP-1 receptor agonist approved by the FDA in April 2026 for chronic weight management. Randomised phase 3 trials report mean weight reductions in the range of roughly 8% to 12% at the highest dose, substantially below injectable dual agonists but achieved without peptide manufacturing constraints or food and water restrictions.
the explanation
Orforglipron is a pill rather than an injection, and unlike earlier oral versions it can be taken any time of day with or without food. It produced around 10 percent weight loss, less than the injectable drugs, but it is far easier to manufacture and take.
regulatory status
FDA-approved April 2026 (Foundayo)
Approved 1 April 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, as a once-daily 6 mg, 12 mg or 36 mg oral tablet.
how it works · proposed mechanism
Orforglipron reaches the same receptor as injectable GLP-1 drugs by a completely different chemical route.
Small molecule, same receptor
Orforglipron is a non-peptide molecule that activates the GLP-1 receptor by binding its transmembrane region rather than mimicking the peptide hormone. This avoids the gastrointestinal degradation that forces peptides to be injected.
No food or water constraints
Unlike oral semaglutide, which requires fasting administration with a strict water volume and waiting period, orforglipron can be taken at any time without regard to food. This removes the main real-world adherence barrier of oral peptide delivery.
Biased partial agonism
Orforglipron acts as a partial agonist with signalling bias favouring cAMP accumulation over beta-arrestin recruitment. This pharmacology may explain why efficacy plateaus below full peptide agonists despite adequate exposure.
Manufacturing at scale
Small-molecule synthesis avoids the peptide solid-phase manufacturing bottleneck that has constrained incretin supply. This is a supply and cost argument rather than a clinical efficacy one.
what’s reported
evidence shape
5 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Efficacy is roughly half that of tirzepatide: ATTAIN-1 reported 12.4% weight loss at the 36 mg dose on the efficacy estimand and −11.2% on the treatment-regimen estimand, against roughly −20% for tirzepatide in SURMOUNT-5. Discontinuation for adverse events also climbed dose-dependently to 10.3% at 36 mg versus 2.7% on placebo, so the tolerability cost is not trivial for the smaller effect.
key published findings
- ATTAIN-1 (n=3,127, 72 weeks, 10 countries) reported mean weight reductions of 7.8%, 9.3% and 12.4% at 6 mg, 12 mg and 36 mg versus 0.9% on placebo, published in NEJM in September 2025.
- ATTAIN-1 reported adverse-event discontinuation rising dose-dependently at 5.3%, 7.9% and 10.3% for 6/12/36 mg versus 2.7% on placebo.
- ATTAIN-2 (n=1,613, 72 weeks) in adults with type 2 diabetes reported weight reductions of −5.1% to −9.6% versus −2.5% on placebo, with significant HbA1c improvement.
- At the 36 mg dose in ATTAIN-1, 54.6% of participants achieved at least 10% body-weight reduction.
- The FDA approved orforglipron as Foundayo on 1 April 2026, making it the first oral GLP-1 receptor agonist for weight management without food or water administration restrictions.
limitations of the evidence
- No cardiovascular outcomes trial has reported, so unlike semaglutide there is no hard-endpoint evidence for orforglipron.
- No adequately powered head-to-head trial against tirzepatide or injectable semaglutide for weight loss has been published; comparisons are cross-trial.
- Long-term safety data beyond 72 weeks are limited, and hepatic safety signals seen in some earlier oral GLP-1 programmes warrant continued post-marketing surveillance.
identity
| full name | Orforglipron (LY3502970, OWL833; non-peptide oral GLP-1 receptor agonist) |
| category | Metabolic |
| modality | small molecule |
| formula | C48H48F2N10O5 |
| molar mass | 882.97 g/mol |
| cas | 2212020-52-3 |
| half-life | 29–49 hours |
laboratory handling
| storage | As a small molecule rather than a peptide, powdered reference material is typically stored at −20 °C protected from light and moisture; DMSO stock solutions are commonly aliquoted and held at −80 °C, with vendor stability data generally citing months rather than days. |
| solubility | Soluble in DMSO for in vitro laboratory stock preparation; poorly soluble in water, so aqueous working solutions are typically prepared by dilution from DMSO stock with co-solvents. |
| co-studied with | A phase 3 switch trial has evaluated transitioning from injectable incretins to oral orforglipron for weight maintenance. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
5 citedNEJM / Eli Lilly · 2025 · official
Eli Lilly and Company · 2026 · official
Drugs.com · 2026 · official
Pharmacy Times · 2026 · review
Wikipedia / Cayman Chemical · 2026 · tertiary
Sources marked tertiary or press release are the weakest citations on this page.
others in Metabolic